A Bridge for Therapeutic Innovation

ASAJES

Ventures

THE

BRIDGE

A bridge for therapeutic innovation

More than ever, the demand for better healthcare in Asia is high and growing.

Today, some US and European innovators have the potential to meet the challenge, but the Asian’s drug market often seems too complex for young biopharmaceutical companies.

Each individual country presents a unique set of political socioeconomic, geographical and cultural features and distinct disease profiles, regulatory issues and local competitors.

De-risk and speed-up access to Asian drug market

To successfully address this complexity, ASAJES Ventures leads the capital investment, development, market access and licensing of late-clinical stage drug candidates originated from western countries.

Founded by Dr. Chika YOSHINAGA, who has an exceptional background in venture capital, pharmaceutical business development and clinical operations in Japan and China, and Dr. Hervé BRAILLY, a French pioneer of biopharmaceutical industry, ASAJES Ventures thus offers small and mid-size biopharma a two-in-one healthcare investment fund combining tailor-made investment and clinical development operations.

THE BRIDGE